DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Jetrea (Ocriplasmin) - Summary

 
 



JETREA SUMMARY

Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.

JETREA® is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.


See all Jetrea indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Jetrea (Ocriplasmin)

Jetrea Gets FDA Nod for Macular Adhesion
Source: MedPage Today Product Alert [2012.10.19]
WASHINGTON -- The FDA has approved ocriplasmin (Jetrea) as the first nonsurgical treatment for symptomatic vitreomacular adhesion.

more news >>

Clinical Trials Related to Jetrea (Ocriplasmin)

Assessment of Patients Treated With JETREA� for Vitreomacular Traction [Active, not recruiting]
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.

The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV) [Completed]
To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 g dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)

A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III) [Completed]

A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt) [Completed]
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction.

Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. [Completed]
This trial will evaluate the safety and efficacy of microplasmin, administered as an intravitreal injection, in subjects with focal vitreomacular adhesion. In previously performed clinical trials, some patients treated with intravitreal microplasmin have had resolution of their underlying condition, including macular hole closure, without need for vitrectomy. This clinical trial is justified because the sponsor believes the potential benefits outweigh the potential risks.

more trials >>


Page last updated: 2012-10-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017